Cargando…

Inhibitory effects of a selective Jak2 inhibitor on adrenocorticotropic hormone production and proliferation of corticotroph tumor AtT20 cells

PURPOSE: The primary cause of Cushing’s disease is adrenocorticotropic hormone (ACTH)-producing pituitary adenomas. EGFR signaling induces POMC mRNA-transcript levels and ACTH secretion from corticotroph tumors. The Jak–STAT pathway is located downstream of EGFR signaling; therefore, a Jak2 inhibito...

Descripción completa

Detalles Bibliográficos
Autores principales: Asari, Yuko, Kageyama, Kazunori, Nakada, Yuki, Tasso, Mizuki, Takayasu, Shinobu, Niioka, Kanako, Ishigame, Noriko, Daimon, Makoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5590765/
https://www.ncbi.nlm.nih.gov/pubmed/28919782
http://dx.doi.org/10.2147/OTT.S141345
_version_ 1783262582648340480
author Asari, Yuko
Kageyama, Kazunori
Nakada, Yuki
Tasso, Mizuki
Takayasu, Shinobu
Niioka, Kanako
Ishigame, Noriko
Daimon, Makoto
author_facet Asari, Yuko
Kageyama, Kazunori
Nakada, Yuki
Tasso, Mizuki
Takayasu, Shinobu
Niioka, Kanako
Ishigame, Noriko
Daimon, Makoto
author_sort Asari, Yuko
collection PubMed
description PURPOSE: The primary cause of Cushing’s disease is adrenocorticotropic hormone (ACTH)-producing pituitary adenomas. EGFR signaling induces POMC mRNA-transcript levels and ACTH secretion from corticotroph tumors. The Jak–STAT pathway is located downstream of EGFR signaling; therefore, a Jak2 inhibitor could be an effective therapy for EGFR-related tumors. In this study, we determined the effect of a potent and selective Jak2 inhibitor, SD1029, on ACTH production and proliferation in mouse AtT20 corticotroph tumor cells. MATERIALS AND METHODS: AtT20 pituitary corticotroph tumor cells were cultured after transfection with PTTG1- or GADD45β-specific siRNA. Expression levels of mouse POMC, PTTG1, and GADD45β mRNAs were evaluated using quantitative real-time polymerase chain reaction. ACTH levels were measured using ACTH ELISA. Western blot analysis was performed to examine protein expression of phosphorylated STAT3/STAT3. Viable cells and DNA fragmentation were measured using a cell-proliferation assay and cell-death detection ELISA, respectively. Cellular DNA content was analyzed using fluorescence-activated cell sorting. RESULTS: SD1029 decreased POMC and PTTG1 mRNA and ACTH levels, while increasing GADD45β levels. The drug also decreased AtT20-cell proliferation and induced apoptosis, but did not alter cell-cycle progression. SD1029 also inhibited STAT3 phosphorylation. PTTG1 knockdown inhibited POMC mRNA levels and cell proliferation. However, combined treatment with PTTG1 knockdown and SD1029 had no additive effect on POMC mRNA levels or cell proliferation. GADD45β knockdown inhibited the SD1029-induced decrease in POMC mRNA levels and also partially inhibited the decrease in cell proliferation. CONCLUSION: Both PTTG1 and GADD45β may be responsible, at least in part, for the Jak2-induced suppression of ACTH synthesis and cell proliferation. Accordingly, therapies that target EGFR-dependent Jak2/STAT3 may have clinical applications for treating Cushing’s disease.
format Online
Article
Text
id pubmed-5590765
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-55907652017-09-15 Inhibitory effects of a selective Jak2 inhibitor on adrenocorticotropic hormone production and proliferation of corticotroph tumor AtT20 cells Asari, Yuko Kageyama, Kazunori Nakada, Yuki Tasso, Mizuki Takayasu, Shinobu Niioka, Kanako Ishigame, Noriko Daimon, Makoto Onco Targets Ther Original Research PURPOSE: The primary cause of Cushing’s disease is adrenocorticotropic hormone (ACTH)-producing pituitary adenomas. EGFR signaling induces POMC mRNA-transcript levels and ACTH secretion from corticotroph tumors. The Jak–STAT pathway is located downstream of EGFR signaling; therefore, a Jak2 inhibitor could be an effective therapy for EGFR-related tumors. In this study, we determined the effect of a potent and selective Jak2 inhibitor, SD1029, on ACTH production and proliferation in mouse AtT20 corticotroph tumor cells. MATERIALS AND METHODS: AtT20 pituitary corticotroph tumor cells were cultured after transfection with PTTG1- or GADD45β-specific siRNA. Expression levels of mouse POMC, PTTG1, and GADD45β mRNAs were evaluated using quantitative real-time polymerase chain reaction. ACTH levels were measured using ACTH ELISA. Western blot analysis was performed to examine protein expression of phosphorylated STAT3/STAT3. Viable cells and DNA fragmentation were measured using a cell-proliferation assay and cell-death detection ELISA, respectively. Cellular DNA content was analyzed using fluorescence-activated cell sorting. RESULTS: SD1029 decreased POMC and PTTG1 mRNA and ACTH levels, while increasing GADD45β levels. The drug also decreased AtT20-cell proliferation and induced apoptosis, but did not alter cell-cycle progression. SD1029 also inhibited STAT3 phosphorylation. PTTG1 knockdown inhibited POMC mRNA levels and cell proliferation. However, combined treatment with PTTG1 knockdown and SD1029 had no additive effect on POMC mRNA levels or cell proliferation. GADD45β knockdown inhibited the SD1029-induced decrease in POMC mRNA levels and also partially inhibited the decrease in cell proliferation. CONCLUSION: Both PTTG1 and GADD45β may be responsible, at least in part, for the Jak2-induced suppression of ACTH synthesis and cell proliferation. Accordingly, therapies that target EGFR-dependent Jak2/STAT3 may have clinical applications for treating Cushing’s disease. Dove Medical Press 2017-09-01 /pmc/articles/PMC5590765/ /pubmed/28919782 http://dx.doi.org/10.2147/OTT.S141345 Text en © 2017 Asari et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Asari, Yuko
Kageyama, Kazunori
Nakada, Yuki
Tasso, Mizuki
Takayasu, Shinobu
Niioka, Kanako
Ishigame, Noriko
Daimon, Makoto
Inhibitory effects of a selective Jak2 inhibitor on adrenocorticotropic hormone production and proliferation of corticotroph tumor AtT20 cells
title Inhibitory effects of a selective Jak2 inhibitor on adrenocorticotropic hormone production and proliferation of corticotroph tumor AtT20 cells
title_full Inhibitory effects of a selective Jak2 inhibitor on adrenocorticotropic hormone production and proliferation of corticotroph tumor AtT20 cells
title_fullStr Inhibitory effects of a selective Jak2 inhibitor on adrenocorticotropic hormone production and proliferation of corticotroph tumor AtT20 cells
title_full_unstemmed Inhibitory effects of a selective Jak2 inhibitor on adrenocorticotropic hormone production and proliferation of corticotroph tumor AtT20 cells
title_short Inhibitory effects of a selective Jak2 inhibitor on adrenocorticotropic hormone production and proliferation of corticotroph tumor AtT20 cells
title_sort inhibitory effects of a selective jak2 inhibitor on adrenocorticotropic hormone production and proliferation of corticotroph tumor att20 cells
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5590765/
https://www.ncbi.nlm.nih.gov/pubmed/28919782
http://dx.doi.org/10.2147/OTT.S141345
work_keys_str_mv AT asariyuko inhibitoryeffectsofaselectivejak2inhibitoronadrenocorticotropichormoneproductionandproliferationofcorticotrophtumoratt20cells
AT kageyamakazunori inhibitoryeffectsofaselectivejak2inhibitoronadrenocorticotropichormoneproductionandproliferationofcorticotrophtumoratt20cells
AT nakadayuki inhibitoryeffectsofaselectivejak2inhibitoronadrenocorticotropichormoneproductionandproliferationofcorticotrophtumoratt20cells
AT tassomizuki inhibitoryeffectsofaselectivejak2inhibitoronadrenocorticotropichormoneproductionandproliferationofcorticotrophtumoratt20cells
AT takayasushinobu inhibitoryeffectsofaselectivejak2inhibitoronadrenocorticotropichormoneproductionandproliferationofcorticotrophtumoratt20cells
AT niiokakanako inhibitoryeffectsofaselectivejak2inhibitoronadrenocorticotropichormoneproductionandproliferationofcorticotrophtumoratt20cells
AT ishigamenoriko inhibitoryeffectsofaselectivejak2inhibitoronadrenocorticotropichormoneproductionandproliferationofcorticotrophtumoratt20cells
AT daimonmakoto inhibitoryeffectsofaselectivejak2inhibitoronadrenocorticotropichormoneproductionandproliferationofcorticotrophtumoratt20cells